20
SEP
2017
NW BIO Announces Registered Direct Offering Of $1.75 Million
Comments : Off
BETHESDA, Md., September 20, 2017 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with institutional investors for a registered direct offering with gross proceeds of $1.75 million. In the transaction, the Company will sell approximately 8.75 million shares of common stock... Read More